Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter (Q2) and First Half (H1) ended June 30, 2025
Business Overview: GSK is a global biopharma company focused on Specialty Medicines (HIV, Respiratory, Immunology & Inflammation, Oncology), Vaccines, and General Medicines. The period was characterized by strong performance in Specialty Medicines and Vaccines, offset by declines in General Medicines due to generic competition and pricing pressures.
Key Financial Metrics (Q2 2025)
| Metric | Q2 2025 (£m) | Growth (AER%) | Growth (CER%) |
|---|---|---|---|
| Turnover | 7,986 | +1% | +6% |
| Total Operating Profit | 2,023 | +23% | +33% |
| Total Operating Margin | 25.3% | +4.5 ppts (AER) / +5.4 ppts (CER) | |
| Core Operating Profit | 2,631 | +5% | +12% |
| Core Operating Margin | 32.9% | +1.1 ppts (AER) / +1.8 ppts (CER) | |
| Total EPS | 35.5p | +23% | +35% |
| Core EPS | 46.5p | +7% | +15% |
| Cash Generated from Operations | 2,433 | +47% | N/A |
| Free Cash Flow | 1,126 | >100% | N/A |
| Net Debt | 13,735 | As of June 30, 2025 |
Note: AER = Actual Exchange Rates; CER = Constant Exchange Rates. Growth figures are primarily driven by underlying business performance, with currency impacts noted in the text.
Material Changes vs. Prior Period
- Revenue Mix: Specialty Medicines sales grew 15% (CER) to £3.3 billion, driven by double-digit growth in HIV (+12%), Oncology (+42%), and Respiratory, Immunology & Inflammation (+10%). Vaccines sales grew 9% (CER) to £2.1 billion. Conversely, General Medicines declined 6% (CER) to £2.6 billion, impacted by generic competition and pricing adjustments.
- Profitability: Total Operating Profit surged 33% (CER) primarily due to lower charges for contingent consideration liabilities (CCL) and favorable royalty income, partially offset by intangible asset impairments (£471 million related to the belrestotug programme). Core Operating Profit grew 12% (CER), reflecting organic growth and disciplined investment.
- Product Performance:
- HIV: Long-acting medicines (Cabenuva, Apretude) drove significant growth (+46% and +50% respectively).
- Oncology: Jemperli sales grew 91% (CER) following FDA approval expansion; Ojjaara/Omjjara grew 69% (CER). Zejula declined 5% (CER) due to pricing and volume pressures.
- Vaccines: Shingrix grew 6% (CER) with strong European uptake; Meningitis vaccines grew 22% (CER). Arexvy (RSV) declined year-to-date due to limited US recommendations.
- Balance Sheet: Net debt increased to £13.7 billion from £13.1 billion at year-end 2024, driven by acquisitions (IDRx, Cellphenomics), dividends, and share buybacks, partially offset by strong free cash flow.
Guidance, Outlook, and Risks
2025 Guidance Revision (CER)
GSK has revised its full-year 2025 guidance, now expecting performance towards the top end of the previously stated ranges:
- Turnover Growth: 3% to 5% (previously 3% to 5%)
- Core Operating Profit Growth: 6% to 8% (previously 6% to 8%)
- Core EPS Growth: 6% to 8% (previously 6% to 8%)
Segment Outlook: Specialty Medicines expected to grow at a low-teens percentage; Vaccines expected to be broadly stable to low-single-digit decline; General Medicines expected to be broadly stable.
Management Commentary
CEO Emma Walmsley highlighted strong momentum driven by Specialty Medicines and progress in R&D, including three major FDA approvals in 2025 (Penmenvy, Blujepa, Nucala for COPD). The company remains confident in its long-term outlooks.
Risks and Contingencies
- Regulatory & Legal: Ongoing Zantac and Avandia litigation; new patent infringement suits initiated against Pfizer/BioNTech and Moderna regarding COVID-19 vaccines. FDA advisory committee vote on Blenrep was negative, with a new PDUFA date set for October 2025.
- Geopolitical & Trade: US Section 232 investigation into pharmaceutical imports; potential impact of tariffs on national security and trade. Guidance includes tariffs enacted thus far.
- Pipeline: Risk of delays or failure in delivering pipeline assets, specifically noted as a principal risk for 2025.
Investor Verification Checklist
- Core vs. Total Reconciliation: Verify the impact of the £471 million intangible impairment and CCL remeasurements on the difference between Total and Core Operating Profit.
- Share Buyback Execution: Confirm the pace of the £2 billion share buyback programme (currently £822 million spent in H1 2025) and its impact on diluted EPS.
- US Pricing Pressures: Assess the ongoing impact of the Inflation Reduction Act (IRA) Medicare Part D redesign on Nucala, Trelegy, and HIV products in the US market.
- Blenrep Regulatory Path: Monitor the FDA decision expected on October 23, 2025, following the negative ODAC vote, as this impacts Oncology growth projections.
- Acquisition Integration: Review the provisional accounting and integration costs for recent acquisitions (IDRx, Cellphenomics, and the post-balance sheet efimosfermin acquisition).